Sanofi (SNYNF)
| Market Cap | 115.08B |
| Revenue (ttm) | 53.71B |
| Net Income (ttm) | 10.72B |
| Shares Out | n/a |
| EPS (ttm) | 8.65 |
| PE Ratio | 10.74 |
| Forward PE | 9.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164 |
| Average Volume | 33,184 |
| Open | 96.15 |
| Previous Close | 94.40 |
| Day's Range | 96.15 - 96.15 |
| 52-Week Range | 90.05 - 122.03 |
| Beta | 0.44 |
| RSI | 48.61 |
| Earnings Date | Oct 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Britain is ‘a terrible place’ to sell medicines, says drug firm executive
Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments Business live – latest updates A senior pharmaceuticals executive has called on the governmen...
Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...
Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help protec...
Sanofi (SNY) Gains China Approval for Groundbreaking Diabetes Drug
Sanofi (SNY) Gains China Approval for Groundbreaking Diabetes Drug
Sanofi’s Tzield approved in China to delay type 1 diabetes progression
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Sanofi (SNY) Gains Morgan Stanley Upgrade Amid Promising Drug Data
Sanofi (SNY) Gains Morgan Stanley Upgrade Amid Promising Drug Data
Sanofi upgraded at Morgan Stanley on potential of amlitelimab vs. Dupixent
Morgan Stanley upgrades Sanofi to overweight after strong amlitelimab data for eczema. Read more here.
Morgan Stanley Upgrades Sanofi (SNY) to Overweight, Raises Price Target | SNY Stock News
Morgan Stanley Upgrades Sanofi (SNY) to Overweight, Raises Price Target | SNY Stock News
This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Notable healthcare headlines for the week: Novartis, Cigna and Sanofi in focus
Get the latest S&P 500 healthcare sector updates, market movers, and key pharma deals.
Today's moving stocks: American Eagle, Figma, T. Rowe Price, Amazon, Sanofi
Here are the stocks making the biggest moves on Sept. 4, 2025
Sanofi (SNY) Shares Drop Following Eczema Drug Trial Results
Sanofi (SNY) Shares Drop Following Eczema Drug Trial Results
Sanofi market value tanks following weak results on eczema drug trials
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab...
Why Is Sanofi Stock Falling Thursday?
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. Latest Ratings for ... Full story available on...
Why Is Sanofi Stock Falling Thursday?
On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre...
Sanofi Drops As Eczema Drug Faces Big Test
Sanofi Drops As Eczema Drug Faces Big Test
European Stocks Rise Amid Bond Market Stability; Sanofi (SNY) Falls on Drug Trial Results
European Stocks Rise Amid Bond Market Stability; Sanofi (SNY) Falls on Drug Trial Results
Sanofi Drops As Eczema Drug Faces Big Test(EDIT)
Sanofi Drops As Eczema Drug Faces Big Test(EDIT)
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA (NASDAQ: SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match inves...
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta...
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.